What are the latest advancements in acute myeloid leukemia therapy?

Abstract

Future OncologyVol. 13, No. 10 CommentaryWhat are the latest advancements in acute myeloid leukemia therapy?Aaron Goodman & Edward D BallAaron Goodman*Author for correspondence: E-mail Address: a1goodman@ucsd.edu Department of Medicine, Division of Blood & Marrow Transplantation, University of California, San Diego Moores Cancer Center, San Diego, CA, USA Department of Medicine, Division of Hematology/Oncology, University of California, San Diego Moores Cancer Center, San Diego, CA, USASearch for more papers by this author & Edward D Ball Department of Medicine, Division of Blood & Marrow Transplantation, University of California, San Diego Moores Cancer Center, San Diego, CA, USASearch for more papers by this authorPublished Online:27 Feb 2017https://doi.org/10.2217/fon-2016-0555AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: AMLantibody–drug conjugatestargeted agentstherapyReferences1 Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N. Engl. J. Med. 373(12), 1136–1152 (2015).Crossref, Medline, Google Scholar2 Buckley SA, Walter RB. Antigen-specific immunotherapies for acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program 2015, 584–595 (2015).Crossref, Medline, Google Scholar3 Stein EM. Molecularly targeted therapies for acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program 2015, 579–583 (2015).Crossref, Medline, Google Scholar4 Coombs CC, Tallman MS, Levine RL. Molecular therapy for acute myeloid leukaemia. Nat. Rev. Clin. Oncol. 13(5), 305–318 (2015).Crossref, Medline, Google Scholar5 Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 118(23), 6006–6017 (2011).Crossref, Medline, CAS, Google Scholar6 Lancet JE, Cortes JE, Hogge DE et al. Phase II, multicenter, randomized, open label trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients with untreated AML 60–75 years of age. Blood 123(21), 3239–3246 (2014).Crossref, Medline, CAS, Google Scholar7 Lancet JE, Uy GL, Cortes JE et al. Final results of a Phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML (Abstract). J. Clin. Oncol. 34(Suppl.), Abstract 7000 (2016).Google Scholar8 Lancet JE, Hoering A, Uy GL et al. Survival following allogeneic hematopoietic cell transplantation in older high-risk acute myeloid leukemia patients initially treated with CPX-351 liposome injection versus standard cytarabine and daunorubicin: subgroup analysis of a large Phase III trial (Abstract). Blood 128(22), 906 (3026).Google Scholar9 Kantarjian HM, Jabbour EJ, Garcia-Manero G et al. Phase I/II study of DFP-10917 in relapsed/refractory AML demonstrates efficacy and safety profile suitable for Phase III study (Abstract). Blood 128(22), 2822 (2016).Crossref, Google Scholar10 Wadleigh M, Richardson PG, Zahrieh D et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 102(5), 1578–1582 (2003).Crossref, Medline, CAS, Google Scholar11 Erba HP, Levy MY, Vasu S et al. A Phase 1b study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed acute myeloid leukemia (AML) (Abstract). Blood 128(22), 211 (2016).Crossref, Google Scholar12 Bixby DL, Stein AS, Fathi AT et al. Vadastuximab talirine monotherapy in older patients with treatment naive cd33-positive acute myeloid leukemia (AML) (Abstract). Blood 128(22), 590 (2016).Crossref, Google Scholar13 Fathi AT, Erba HP, Lancet JE et al. Vadastuximab talirine plus hypomethylating agents: a well-tolerated regimen with high remission rate in frontline older patients with acute myeloid leukemia (AML) (Abstract). Blood 128(22), 591 (2016).Crossref, Google Scholar14 Araki D, Wood BL, Othus M et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J. Clin. Oncol. 34(4), 329–336 (2016).Crossref, Medline, Google Scholar15 Jurcic JG, Levy MY, Park JH et al. Phase I trial of targeted alpha-particle therapy with actinium-225 (225Ac)-lintuzumab and low-dose cytarabine (LDAC) in patients age 60 or older with untreated acute myeloid leukemia (AML) (Abstract). Blood 128(22), 4050 (2016).Crossref, Google Scholar16 Daver N, Garcia-Manero G, Basu S et al. Phase IB/II study of lirilumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML) (Abstract). Blood 128(22), 1641 (2016).Crossref, Google Scholar17 Gaudet F, Nemeth JF, McDaid R et al. Development of a CD123xCD3 bispecific antibody (JNJ-63709178) for the treatment of acute myeloid leukemia (AML) (Abstract). Blood 128(22), 2824 (2016).Crossref, Medline, Google Scholar18 Lane AA, Sweet KL, Wang ES et al. Results from ongoing Phase 2 trial of SL-401 as consolidation therapy in patients with acute myeloid leukemia (AML) in remission with high relapse risk including minimal residual disease (MRD) (Abstract). Blood 128(22), 215 (2016).Crossref, Google Scholar19 Swords RT, Coutre S, Maris MB et al. Results of a clinical study of pevonedistat (Pev), a first-in-class NEDD8-activating enzyme (NAE) inhibitor, combined with azacitidine (Aza) in older patients (Pts) with acute myeloid leukemia (AML) (Abstract). Blood 128(22), 98 (2016).Crossref, Google Scholar20 Stone RM, Mandrekar S, Sanford BL et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]) (Abstract). Blood 126(23), 6 (2015).Medline, Google Scholar21 Maziarz RT, Patnaik MM, Scott BL et al. Radius: a Phase 2, randomized trial of standard of care (SOC) with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplant (alloHSCT) in patients (pts) with FLT3-Itd-mutated acute myeloid leukemia (AML) (Abstract). Blood 128(22), 2248 (2016).Crossref, Google Scholar22 Wang ES, Stone RM, Tallman MS, Walter RB, Eckardt JR, Collins R. Crenolanib, a type I FLT3 TKI, can be safely combined with cytarabine and anthracycline induction chemotherapy and results in high response rates in patients with newly diagnosed FLT3 mutant acute myeloid leukemia (AML) (Abstract). Blood 128(22), 1071 (2016).Crossref, Google Scholar23 Konopleva M, Pollyea DA, Potluri J et al. Efficacy and biological correlates of response in a Phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6(10), 1106–1117 (2016).Crossref, Medline, CAS, Google Scholar24 Pollyea DA, Dinardo CD, Thirman MJ et al. Results of a Phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy (Abstract). J. Clin. Oncol. 34(Suppl.), Abstract 7009 (2016).Google Scholar25 Wei A, Strickland SA, Roboz GJ et al. Safety and efficacy of venetoclax plus low-dose cytarabine in treatment-naive patients aged ≥65 years with acute myeloid leukemia (Abstract). Blood 128(22), 102 (2016).Crossref, Google Scholar26 Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14(10), 3044–3051 (2008).Crossref, Medline, CAS, Google Scholar27 Daver N, Basu S, Garcia-Manero G et al. Phase IB/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML) (Abstract). Blood 128(22), 763 (2016).Crossref, Medline, Google Scholar28 Davids MS, Kim HT, Bachireddy P et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl. J. Med. 375(2), 143–153 (2016).Crossref, Medline, CAS, Google Scholar29 Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat. Rev. Clin. Oncol. 13(6), 370–383 (2016).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 13, No. 10 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 161 times History Published online 27 February 2017 Published in print April 2017 Information© Future Medicine LtdKeywordsAMLantibody–drug conjugatestargeted agentstherapyFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download